Adjuvant endocrine therapy for breast cancer: how long is long enough?

Rachel C. Jankowitz, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

Although women with early-stage hormone receptor-positive breast cancer have low recurrence rates initially, they have a constant and unrelenting risk of relapse that extends up to 15 years despite the use of adjuvant therapy. Increasing evidence supports the use of extended endocrine therapy with either tamoxifen or an aromatase inhibitor (AI) after 5 years of initial adjuvant tamoxifen to reduce breast cancer recurrence and mortality. However, the optimal total duration of AI therapy, as well as the ideal timing of sequencing from tamoxifen to an AI, is still unclear. Potential strategies differ depending on a woman's menopausal status at the time of her initial diagnosis. Individual patient clinical factors and preferences can help with decision making until further data emerge on prolonged AI use and on potential biomarkers that can be used to tailor adjuvant endocrine treatment.

Original languageEnglish (US)
JournalUnknown Journal
Volume27
Issue number12
StatePublished - 2013
Externally publishedYes

Fingerprint

Aromatase Inhibitors
inhibitor
cancer
Tamoxifen
Breast Neoplasms
Recurrence
womens status
Women's Rights
Therapeutics
hormone
biomarker
Decision Making
Biomarkers
decision making
Hormones
mortality
Mortality
therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant endocrine therapy for breast cancer : how long is long enough? / Jankowitz, Rachel C.; Davidson, Nancy E.

In: Unknown Journal, Vol. 27, No. 12, 2013.

Research output: Contribution to journalArticle

Jankowitz, RC & Davidson, NE 2013, 'Adjuvant endocrine therapy for breast cancer: how long is long enough?', Unknown Journal, vol. 27, no. 12.
Jankowitz, Rachel C. ; Davidson, Nancy E. / Adjuvant endocrine therapy for breast cancer : how long is long enough?. In: Unknown Journal. 2013 ; Vol. 27, No. 12.
@article{80dd56a9dbc24cc491989789f930e63e,
title = "Adjuvant endocrine therapy for breast cancer: how long is long enough?",
abstract = "Although women with early-stage hormone receptor-positive breast cancer have low recurrence rates initially, they have a constant and unrelenting risk of relapse that extends up to 15 years despite the use of adjuvant therapy. Increasing evidence supports the use of extended endocrine therapy with either tamoxifen or an aromatase inhibitor (AI) after 5 years of initial adjuvant tamoxifen to reduce breast cancer recurrence and mortality. However, the optimal total duration of AI therapy, as well as the ideal timing of sequencing from tamoxifen to an AI, is still unclear. Potential strategies differ depending on a woman's menopausal status at the time of her initial diagnosis. Individual patient clinical factors and preferences can help with decision making until further data emerge on prolonged AI use and on potential biomarkers that can be used to tailor adjuvant endocrine treatment.",
author = "Jankowitz, {Rachel C.} and Davidson, {Nancy E.}",
year = "2013",
language = "English (US)",
volume = "27",
journal = "Advances in Water Resources",
issn = "0309-1708",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Adjuvant endocrine therapy for breast cancer

T2 - how long is long enough?

AU - Jankowitz, Rachel C.

AU - Davidson, Nancy E.

PY - 2013

Y1 - 2013

N2 - Although women with early-stage hormone receptor-positive breast cancer have low recurrence rates initially, they have a constant and unrelenting risk of relapse that extends up to 15 years despite the use of adjuvant therapy. Increasing evidence supports the use of extended endocrine therapy with either tamoxifen or an aromatase inhibitor (AI) after 5 years of initial adjuvant tamoxifen to reduce breast cancer recurrence and mortality. However, the optimal total duration of AI therapy, as well as the ideal timing of sequencing from tamoxifen to an AI, is still unclear. Potential strategies differ depending on a woman's menopausal status at the time of her initial diagnosis. Individual patient clinical factors and preferences can help with decision making until further data emerge on prolonged AI use and on potential biomarkers that can be used to tailor adjuvant endocrine treatment.

AB - Although women with early-stage hormone receptor-positive breast cancer have low recurrence rates initially, they have a constant and unrelenting risk of relapse that extends up to 15 years despite the use of adjuvant therapy. Increasing evidence supports the use of extended endocrine therapy with either tamoxifen or an aromatase inhibitor (AI) after 5 years of initial adjuvant tamoxifen to reduce breast cancer recurrence and mortality. However, the optimal total duration of AI therapy, as well as the ideal timing of sequencing from tamoxifen to an AI, is still unclear. Potential strategies differ depending on a woman's menopausal status at the time of her initial diagnosis. Individual patient clinical factors and preferences can help with decision making until further data emerge on prolonged AI use and on potential biomarkers that can be used to tailor adjuvant endocrine treatment.

UR - http://www.scopus.com/inward/record.url?scp=84890517285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890517285&partnerID=8YFLogxK

M3 - Article

C2 - 24624537

VL - 27

JO - Advances in Water Resources

JF - Advances in Water Resources

SN - 0309-1708

IS - 12

ER -